Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective

Pashtoon M Kasi, Hussein A Tawbi, Chester V Oddis and Hrishikesh S Kulkarni*

Abstract
The advent of biologic agents has provided a more specific and targeted approach to the treatment of various hematological malignancies and other autoimmune disorders. Such biologic agents have been relatively well tolerated with fewer adverse events reported as compared with many other chemotherapeutic agents. Rituximab is a monoclonal antibody to the B-cell marker CD20 and is a common biologic agent widely used for the treatment of B-cell lymphoma, lymphoproliferative disorders, and inflammatory conditions that are refractory to conventional treatment, including rheumatoid arthritis and some vasculitides. However, through randomized controlled trials and post-marketing surveillance, an increasing number of serious adverse events are being associated with the use of rituximab, often leading to or complicating an intensive care unit admission. The purpose of this review is to focus on the severe complications that are associated with the use of rituximab and that require critical care. Management and prevention strategies for the most common complications along with some examples of its uses within the critical care setting are also discussed.

Introduction
Yearly sales of rituximab in the US already exceed $2 billion, attesting to its increasing US Food and Drug Administration (FDA)-approved and off-label use in multiple clinical settings such as B-cell lymphoma, lymphoproliferative disorders, and refractory inflammatory conditions, including rheumatoid arthritis (RA) (Table 1) [1-5]. By mid-2011, 12,448 adverse events (AEs) associated with rituximab use were publicly reported to the FDA; of these, febrile neutropenia, pyrexia, pneumonia, and anemia were the most common [6]. Rituximab had been implicated as the suspect drug leading to death in 476 cases [6].

The cost of hospitalization due to adverse events associated with rituximab can be substantial, especially when they require an intensive care unit (ICU) admission. In a prospective multicenter study of adverse events associated with rituximab, patients with infusion reactions required significantly more staff time per infusion compared with those in whom no reactions occurred (164 versus 123 minutes) [7]. Grade 3 and 4 (severe, life-threatening) infusion reactions resulted in significantly higher infusion-associated human resource costs compared with when no infusion reactions occurred (median cost of $220 versus $120) [7]. In another study by the same authors, resuscitation carts needed to be used in 23% of patients (11 out of 47) with grade 3 or 4 infusion reactions. ICU admission occurred in two cases. The mean duration of hospitalization for a severe infusion reaction was 4 days [8]. Hence, the increasing frequency of use of rituximab in addition to its potentially serious adverse effects – either alone or in combination with other agents – warrants that intensivists, along with hematologists and rheumatologists, be familiar with the drug, especially when it is used in a critical care setting or when patients develop serious AEs (SAEs) requiring critical care management.

Mechanism of action
Rituximab is a chimeric monoclonal antibody directed against the CD20 B-cell antigen, a non-glycosylated phosphoprotein that is expressed on the surface of all mature B cells (Figure 1) [9]. It is not present on stem cells and is lost prior to B-cell differentiation into plasma cells. Hence, rituximab causes a selective, transient depletion of both the normal and malignant CD20+ B-cell subpopulations and offers a more specific and targeted approach to B cell-driven disorders. In malignancies,
rituximab also synergistically acts to sensitize B cells to other chemotherapeutic regimens [3,9,10].

Figure 1 highlights the postulated mechanisms through which rituximab acts [9,11,12]: (1) antibody-dependent cell-mediated cytotoxicity: presumed predominant mechanism of action in vitro; (2) complement-dependent cytotoxicity; (3) direct effects of the drug: ligand binding leading to apoptosis or sensitization (or both) of the tumor to other chemotherapeutic agents; and (4) antibody-dependent phagocytosis: through both Fc and complement receptors. These effects occur simultaneously and may complement one another, leading to a synergistic effect. This has led to multiple randomized clinical trials showing the beneficial effects of rituximab in many diseases, leading to its increasingly widespread use (Table 1) [13-15].

Dosing
Rituximab is administered as an intravenous infusion [9]. For treatment-naïve patients, it is started at a rate of 50 mg/hour and is increased by 50 mg/hour every 30 minutes to a maximum of 400 mg/hour. Patients are premedicated with an analgesic/antipyretic (for example, acetaminophen), antihistaminic (for example, diphenhydramine), and a steroid (for example, methylprednisolone) 30 minutes prior to the infusion, mainly to minimize the severity of infusion reactions [8,9,16].

Table 1. Common indications for rituximab therapy

| Disease conditions                              |
|-----------------------------------------------|
| Chronic lymphocytic leukemia                  |
| CD20+ non-Hodgkin lymphoma (expressing the B-lymphocyte antigen CD20) |
| Rheumatoid arthritis                          |
| Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis |
| • Granulomatosis with polyangiitis (formerly Wegener’s granulomatosis) |
| • Microscopic polyangiitis                    |
| • Eosinophilic granulomatosis associated with polyangiitis (formerly Churg-Strauss syndrome) (unlabeled) |
| Chronic refractory graft-versus-host disease (unlabeled) |
| Refractory idiopathic thrombocytopenic purpura (unlabeled) |
| Hodgkin lymphoma (unlabeled)                  |
| Refractory pemphigus vulgaris (unlabeled)     |
| Post-transplant lymphoproliferative disorder (unlabeled) |
| Waldenström macroglobulinemia (unlabeled)     |
| Type I diabetes mellitus (unlabeled)          |
| Multiple sclerosis (unlabeled)                |
| Renal transplant (unlabeled)                  |

Uses within the critical care setting

**Rituximab as part of chemotherapeutic regimens**
Rituximab is often administered in the ICU in patients who have lymphoproliferative disorders and who need combination chemotherapy but who have tumor lysis syndrome or are at high risk for this syndrome [17,18] – for example, rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), rituximab with cyclophosphamide, doxorubicin, etoposide, and prednisolone (R-CHVP), rituximab with cyclophosphamide, vincristine, and prednisone (R-CVP), rituximab with fludarabine, cyclophosphamide, and mitoxantrone (R-FCM), and rituximab with mitoxantrone, chlorambucil, and prednisolone (R-MCP). Rituximab is often administered to patients in an ICU when they have a newly diagnosed malignancy with an extensive disease burden, multi-organ involvement, and/or disseminated intravascular coagulation [19].

**Refractory idiopathic thrombocytopenic purpura**
Idiopathic thrombocytopenic purpura (ITP) refractory to steroids and splenectomy can be challenging to treat. These patients may be transferred to an ICU for severe thrombocytopenia because of the risk of spontaneous intracranial bleeding. In patients with refractory ITP, response rates of up to 50% have been reported with rituximab [20].

**Post-transplant lymphoproliferative disorder**
Post-transplant lymphoproliferative disorder (PTLD) is being increasingly diagnosed (1% to 10% of transplant patients) in the setting of prolonged use of immunosuppressants. Rituximab in combination with other chemotherapeutic agents may be used in transplant ICUs, depending on disease severity. However, treatment-associated mortality occurs in up to 11% of patients with PTLD [21,22].

**Thrombotic thrombocytopenic purpura**
Severe thrombotic thrombocytopenic purpura (TTP) is often diagnosed in the ICU or necessitates an ICU admission on presentation. In a phase 2 trial of 40 patients with TTP, rituximab along with plasma exchange significantly decreased the duration of hospitalization and rate of relapse [23].

**Severe interstitial lung disease associated with connective tissue disease**
In a retrospective cohort study of patients with progressive interstitial lung disease (ILD) associated with connective tissue disease not responding to conventional immunosuppressive regimens, rituximab improved lung function in seven of eight patients [24]. Two of these patients were mechanically ventilated. Rituximab along
with cyclophosphamide has also been anecdotally used in the ICU in the treatment of severe ILD associated with antisynthetase syndrome [25].

**Pulmonary vasculitides**
Rituximab has been successfully used in patients who have diffuse alveolar hemorrhage related to systemic lupus erythematosus and who were either intolerant to cyclophosphamide or refractory to conventional immunosuppressive regimens [26,27]. It is also the first proven safe and effective alternative to cyclophosphamide to induce remission in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (Table 1) [28,29].

**Special populations**
Rituximab should be used with caution in older patients and in patients with cardiopulmonary disease [9]. Older patients (more than 55 years of age) have a higher rate of serious cardiopulmonary and infectious complications. Rituximab should also be avoided in any patient with severe infection [9]. It is a category C drug for pregnant women because animal studies have revealed deleterious effects on the fetus and controlled studies in women are lacking or unavailable [9]. Transient B-cell lymphocyte depletion has been reported in infants exposed to rituximab in utero [30]. Hence, it should be considered only if potential benefits outweigh risks to the fetus, such as in non-Hodgkin lymphoma (NHL), refractory moderate-to-severe RA, and granulomatosis with polyangiitis or microscopic polyangiitis [9]. Although rituximab is secreted into the breast milk of lactating monkeys, there are insufficient data for or against its use during breastfeeding in humans [30].
Methods

We searched PubMed using combinations of the following keywords: rituximab, biologics, adverse effects, side effects, toxicity, fatal, death, ICU, shock, cardiotoxicity, hepatotoxicity, neurotoxicity, respiratory failure, and renal failure. Randomized controlled trials, original studies (prospective or retrospective), systematic reviews, review articles, and case reports of patients treated with rituximab as well as relevant references from these papers were scrutinized and included in our review.

A SAE was defined as ‘any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage’ [31]. We included the National Cancer Institute (NCI) Common Toxicity Criteria Grading System to describe the severity of AEs or toxicities whenever they were mentioned in the original articles; higher grades denoted greater severity of toxicity [31] (Table 2). If the severity was not graded, we gave a description of the SAE. We used the same criteria system as proposed by the NCI to group AEs into ‘system organ class’ (SOC), which is identified by anatomical or physiological system, etiology, or purpose [32]. The adverse effects that were likely to be seen during (or that would be associated with) an ICU admission were included in the review. We focused on grade 3, 4, and 5 adverse reactions (Table 2).

Results

Thirty randomized controlled trials and one open-label extension study were included in the review, along with data from post-marketing surveillance and other case reports (see Supplementary File 1). We excluded two articles that were not in English [33,34]. The most common reactions (incidence of at least 25%) in patients receiving rituximab monotherapy were infusion reactions and neutropenia [3,9]. Among these reactions, grade 3 and 4 toxicities were found in 57% of patients (203 out of 356) receiving rituximab [9]. Figure 2 outlines the major SAEs according to the SOCs of the NCI. Under each SOC, we first described reactions likely to occur soon after the administration of rituximab. We then briefly enumerated complications that were associated with more extended administration and that may require intensive care.

Immunologic toxicity

Infusion reactions

Infusion reactions, ascribed to either anaphylaxis or allergic reactions, were the most common SAEs associated with rituximab in 80% to 90% of randomized controlled trials [4,35,36]. Many reactions developed within 24 hours of the first infusion, were dose-dependent, and were often more common in those who received rituximab versus those receiving the conventional chemotherapy regimen [4,14,37-39]. The frequency of the reactions decreased with subsequent cycles, and life-threatening anaphylaxis was rare [14,36,40]. Notably, approximately 80% of all fatal reactions occurred with the first infusion [9].

There are also isolated case reports of severe or fatal SIRS (systemic inflammatory response syndrome)-like reactions (or both) developing within 24 hours of infusing rituximab [25,41]. These are likely a part of the spectrum of the ‘cytokine release syndrome’ that has been described after rituximab infusions in patients with high tumor-cell burden [42]. The reported clinical features included fevers, chills, rigors, nausea, dizziness, pruritus, urticaria/rash, angioedema, laryngeal edema, sneezing, throat irritation/tightness, cough, hoarseness, bronchospasm, pulmonary infiltrates, hypoxia, and acute respiratory insufficiency, with or without blood pressure changes or arrhythmias [4,9]. The severity of reactions was usually mild to moderate (grade 1 or 2); grade 3 to 4 reactions were rare and dose-dependent. For example, in a series of 465 patients treated for RA, acute infusion reactions increased from 17% in placebo-treated patients to 23% and 32% in those receiving two 500-mg infusions and two.

Table 2. Common terminology Criteria for Adverse Events Version 4.0 (CTCAE) [31]

| Grade of toxicity | Brief description |
|-------------------|------------------|
| Grade 1           | Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated |
| Grade 2           | Moderate; minimal, local, or non-invasive intervention indicated; limiting age-appropriate instrumental ADL\textsuperscript{a} |
| Grade 3           | Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL\textsuperscript{b} |
| Grade 4           | Life-threatening consequences; urgent intervention indicated |
| Grade 5           | Death related to adverse event |

\textsuperscript{a}Instrumental ADL refers to activities of daily living such as preparing meals, shopping for groceries or clothes, using the telephone, and managing money. \textsuperscript{b}Self-care ADL refers to bathing, dressing and undressing, feeding oneself, using the toilet, taking medications, and not being bedridden. From the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, DHHS. May 29, 2009 NIH publication #: 09-7473.
1,000-mg infusions of rituximab, respectively [36]. Interestingly, in studies of patients with AEs that are due to rituximab and that may lead to an ICU admission, 62% of patients (47 out of 76) receiving rituximab had a severe infusion reaction, but only two of these patients had a reaction that led to an ICU admission. This shows that many of these infusion reactions may potentially be manageable either under supervision in the outpatient setting or in monitored non-ICU hospital beds [43].

For mild infusion reactions, the rate of infusion was slowed or temporarily interrupted and was resumed at half the previous rate after symptoms abated. For moderate or severe infusion reactions, the infusion was held and subsequent infusions were not administered [9]. Patients were also given acetaminophen and intravenous antihistamine (for example, diphenhydramine) as well as epinephrine, bronchodilators, steroids, and oxygen if needed [8,9,16].

The frequency of infusion reactions, which form the bulk of major SAEs due to rituximab administration, decreased in patients who were premedicated with intravenous glucocorticoids [36]. For example, in the series of 465 patients treated for RA, serious infusion reactions decreased from 32% in the group receiving two 500-mg infusions of rituximab and 37% in the group receiving two 1,000-mg infusions of rituximab to 19% and 29%, respectively, after premedication with intravenous glucocorticoids [36]. These findings were corroborated by a series of renal transplant patients who received induction therapy with rituximab prior to transplantation and who experienced minimal or no side effects and no significant infusion reactions [44]. These patients received 100 mg of oral prednisolone as induction therapy for transplantation and this dose was reduced by 10 mg per day to a daily dose of 20 mg, which was maintained for 1 month. Whether a similar protocol of premedication with glucocorticoids minimizes SAEs in immunologically mediated diseases treated with rituximab remains to be seen, but has been recommended [9].

**Blood and lymphatic system disorders**

Grade 3 and 4 cytopenias lasting approximately 2 weeks have been seen in 48% of patients who had NHL and who received rituximab monotherapy, lymphopenia being the most common [9]. However, cytopenia was more common in chemotherapy trials of regimens in which rituximab was combined with agents more frequently associated with myelosuppression [39,45,46]. For example, granulocytopenia (grades 3 and 4) occurred in 72% of R-CHOP-treated patients compared with 57% of CHOP-treated patients in 64 patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia [45].

Whether these cytopenias have clinical implications is unproven [45,47,48]. In a study of 139 patients with mantle cell lymphoma, leukopenia (grades 3 and 4) occurred in 58% of patients receiving rituximab and a fludarabine-containing regimen (R-FCM) versus 41% in patients who received the fludarabine-containing regimen (FCM) \((P = 0.02)\) [47]. This was mainly due to lymphopenia rather than neutropenia; the frequency and severity of the latter were similar in the two groups. The rate of infections or febrile reactions was no greater in the group of patients receiving rituximab [47]. Thus, although rituximab-augmented chemotherapeutic regimens may cause transient or sustained leukopenia or lymphopenia, the risk of developing serious infections or long-term outcomes is unclear. One reason for this discrepancy is that these studies are not powered to detect serious infections, as is evident by conflicting results [38,47]. Another plausible reason is that, as seen with other drugs, the degree of immunosuppression induced by different doses of a drug may not necessarily correlate with the predisposition to develop a serious infection [49]. Also, the interaction between the underlying disease state and the pharmacotoxicity of an immunosuppressant – either as a single agent or in combination with another drug – may influence this predisposition toward serious infections [38,50,51].
Infections

Although studies have shown an increased frequency of infectious complications with rituximab within 1 year after completion of treatment, most infections either resolved or were treated without any major sequelae. Among 356 patients with lymphoid malignancies treated with rituximab, 31% developed bacterial infections, 10% developed viral infections, and 1% developed fungal infections; in 6%, the etiology was unknown [9]. In a trial of 620 patients with RA, the rate of serious infections was higher in the methotrexate (MTX)-rituximab group compared with the rate in the MTX-placebo group (5.2 versus 3.7 per 100 patient-years) [14]. Six of the serious infections in the MTX-rituximab group – gastroenteritis, pyelonephritis, cat bite infection, influenza, fever of unknown etiology, and de novo hepatitis B virus (HBV) – resolved without sequelae, and one (gangrenous cellulitis) resulted in a toe amputation [14].

There is a dose-dependent increase in the frequency of infections in patients treated with rituximab for varying lengths of time [39]. Although older patients are at an increased risk of developing severe infectious complications, such infections are rarely fatal [4,15,46,52]. For example, in a study of 824 patients with diffuse large B-cell lymphoma, three in the R-CHOP group died of sepsis [52]. Other fatal infections after rituximab administration include pneumonia and colitis [9].

In a review of serious viral infections associated with rituximab use, 64 cases were identified [53]. The median time from rituximab treatment to the diagnosis of the viral infection was approximately 5 months. The most frequently experienced viral infections were HBV infection (39.1%, n = 25), cytomegalovirus infection (23.4%, n = 15), varicella-zoster virus (9.4%, n = 6), and others (28.1%, n = 18) [53]. Patients treated with rituximab carry a risk for HBV reactivation and hence should be screened for HBV prior to starting therapy [9]. This is based on a study from China in which, among 50 patients who had diffuse large B-cell lymphoma and who received rituximab, 60% had reactivation of the virus, 45% had severe hepatitis, and 25% died [54]. HBV reactivation is an indication for discontinuing therapy [9]. Patients with severe HBV have had up to 52% reported mortality compared with 33% in the other patients. There is insufficient evidence either for or against the use of rituximab in patients with latent hepatitis C virus infection [9].

Renal disorders

Urine output and trends in serum creatinine need to be closely monitored in patients receiving rituximab. Acute tumor lysis syndrome (ATLS) leading to acute kidney injury has been observed after rituximab monotherapy, especially in conditions with high tumor burden, like NHL [9]. ATLS results from ‘the rapid destruction of malignant cells, which abruptly release intracellular ions, proteins and metabolites into the extra-cellular space’ [55]. In high concentrations, acutely released uric acid can crystallize in renal tubules, leading to renal insufficiency. Early signs of ATLS include hyperkalemia, hypocalcemia, hyperphosphatemia, or hyperuricemia. Prophylactic measures include intravenous hydration and anti-hyperuricemic therapy (allopurinol) prior to the infusion [9]. Alkalization of the urine is controversial [55]. In high-risk cases (for example, acute leukemia with a white blood cell count of greater than 100,000/mm³, Burkitt lymphoma, or renal insufficiency in the setting of intermittent-risk disease), a single dose of 0.1- to 0.2-mg/kg recombinant urate oxidase (rasburicase), repeated if clinically necessary, can be used to reduce uric acid burden in patients at high risk for ATLS [56]. Management of ATLS is mainly supportive and includes close monitoring of electrolyte abnormalities described above, volume status, and renal function as well as dialysis if necessary [55]. Providers should closely monitor for renal dysfunction when rituximab is combined with cisplatin [9].

Cardiac disorders

Cardiac monitoring is necessary during and after rituximab infusions in all patients with a history of arrhythmias or angina [9]. In a study of 399 older patients with diffuse large B-cell lymphoma treated with either CHOP plus rituximab (R-CHOP) or CHOP alone, approximately 8% of patients in each group developed grade 3 or 4 cardiac AEs [57]. However, supraventricular arrhythmias and tachycardia were higher in the R-CHOP group versus CHOP alone. Similarly, a case of supraventricular tachycardia was reported in a study of patients with RA [13].

Myocardial infarctions have also been reported but are rare [35-37], as were severe hypertension and cardiac tamponade [14]. Rare cases of fatal heart failure have been reported after using rituximab (either as monotherapy or combination chemotherapy), independent of pre-existing heart disease [58-60]. New-onset cardiogenic shock developed in a 20-year-old female treated with rituximab for TTP refractory to plasma exchange [61]. Both acute respiratory failure and biventricular cardiogenic shock improved after rituximab was held and plasma exchange was continued. One case of fatal myocarditis was documented on autopsy in a study of 202 patients treated with rituximab for follicular lymphoma [60].

Respiratory, thoracic, and mediastinal disorders

In a 2011 review of 418 patients treated with rituximab monotherapy, 5.3% developed adverse pulmonary reactions [23]. Approximately two thirds of the reactions were infectious, but nearly one quarter resulted in the
development of ILD. ILD subsequently improved although only half of those patients had received intravenous steroids [23]. Hypoalbuminemia was identified as an independent risk factor for developing adverse pulmonary events.

Rare cases of status asthmaticus, bronchiolitis obliterans, hypersensitivity pneumonitis, and diffuse alveolar hemorrhage (fatal and non-fatal) have also been reported after using rituximab [9,36,62-64]. Bronchiolitis obliterans presenting as cough, dyspnea, and pulmonary nodules has been described in patients receiving rituximab [62]. Hypersensitivity pneumonitis presented as dyspnea, hypoxemia, eosinophilia, and pulmonary infiltrates [63]. Both bronchiolitis obliterans and hypersensitivity pneumonitis due to rituximab improved after stopping rituximab and administering steroids [62,63]. However, the response of diffuse alveolar hemorrhage to steroids was mixed [64].

Neoplastic disorders

In a 2012 review of trials of chemotherapeutic regimens containing rituximab, therapy-related neoplasms were identified in approximately 4.5% of patients (19 out of 426) within a follow-up period of 44 months [65]. Most cases presented as either acute myeloid leukemia or myelodysplastic syndromes and had often previously achieved at least partial (if not complete) remission. The median survival time was approximately 7 months after diagnosis of the therapy-related neoplasms; however, this was not specific to rituximab, since other agents were a part of the chemotherapeutic regimens. The presenting complaint and requirement for ICU admission in these cases are unknown; however, de novo acute myeloid leukemia may be diagnosed in the ICU when patients who have a history of cancer or who recently received chemotherapy present with acute respiratory failure, severe infection, bleeding, or renal dysfunction [66].

Gastrointestinal disorders

New-onset abdominal pain in patients receiving rituximab should prompt investigation for an acute abdomen. In post-marketing surveillance, 47 cases of bowel obstruction (nine deaths) and 37 cases of gastrointestinal perforation (four deaths) were reported by the end of 2006 among patients treated with rituximab, mainly for NHL [67]. In another series of 98 patients treated with combination chemotherapy containing rituximab, there were five severe gastrointestinal complications, including one leading to a death [39]. The average onset of symptoms is approximately 6 days (range of 1 to 77 days) after the first dose [9].

Neurological disorders

The development of new neurological signs in patients receiving rituximab should be evaluated with neuroimaging and a lumbar puncture if there is no other obvious etiology. Among 465 patients treated with rituximab for active RA refractory to MTX, one case each of a cerebrovascular infarction, convolution, epilepsy, and serotonin syndrome were reported [36]. Extremely rare cases of fatal ischemic and hemorrhagic strokes have been reported [9]. Patients have also presented with JC virus reactivation, leading to progressive multifocal leukoencephalopathy [68]. These patients presented within 1 year of rituximab treatment for lymphoid malignancy or autoimmune disorders but had also received either immunosuppressive therapy or stem cell transplants. JC virus can be identified in the cerebrospinal fluid, and the diagnosis of progressive multifocal leukoencephalopathy is an indication to stop rituximab [9].

Dermatologic disorders

In a non-randomized, single-arm study of 356 patients treated for primary cutaneous B-cell lymphomas by using rituximab monotherapy, 37% developed itching, rash, or urticaria [69]. Serious cutaneous side effects occurred in 2% of the study population. Rituximab infusions have been associated with paraneoplastic pemphigus, lichenoid dermatitis, vesiculobullous dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, from immediately after the infusion until 3 months later [70]. Development of these severe reactions should prompt the discontinuation of rituximab [9].

Conclusions

The increasing use of biologics has allowed a more specific and targeted approach to the treatment of various hematological malignancies and other autoimmune disorders in which B-cell or humoral mechanisms appear to play a role in disease pathogenesis. Overall, these biologics appear to be well tolerated and lead to fewer AEs compared with other, more conventional therapies and chemotherapeutic regimens. However, their increasingly widespread and potentially prolonged use poses a new challenge and thus knowledge of SAEs related to rituximab is essential when dealing with patients suffering from such life-threatening complications.

At times, rituximab is administered in an ICU setting, and the intensivist may be the first to be alerted to the acute deterioration of a patient’s clinical status. Rarely, the intensivist may be the accepting physician of a potentially fatal complication in a patient who recently received rituximab. Through our review of the major studies of rituximab and its use in various settings (both as a single agent and in combination therapy), we hope to increase awareness among intensivists regarding the SAEs associated with its use. Early identification and management may help reduce morbidity and mortality associated with these events.
Supplementary file

Supplementary File 1. This online file shows a list of studies included in the review along with rituximab dose used in the clinical trial and system-wide serious adverse events.

Abbreviations
AE, adverse event; ATLs, acute tumor lysis syndrome; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; FCM, fludarabine, cyclophosphamide, and mitoxantrone; FDA, US Food and Drug Administration; HBV, hepatitis B virus; ICU, intensive care unit; IILD, interstitial lung disease; ITP, idiopathic thrombocytopenic purpura; MTX, methotrexate; NCI, National Cancer Institute; NHL, non-Hodgkin lymphoma; PTLD, post-transplant lymphoproliferative disorder; RA, rheumatoid arthritis; R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone; R-FCM, rituximab with fludarabine, cyclophosphamide, and mitoxantrone; SAE, serious adverse event; SOCD, system organ class; TTP, thrombotic thrombocytopenic purpura.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
PMK contributed to the critical review of background literature and the original draft of the manuscript and helped revise the manuscript. HAT and CVO contributed to revising the text and ensuring accuracy of the information contained and edited drafts of the manuscript. HSK contributed to the conception and design of the study, critical review of background literature, and drafting and revising of the manuscript prior to submission and helped revise the manuscript. All authors read and approved the final manuscript.

Acknowledgments
The authors thank Rodrigo Cortin-Ceba, of the Division of Pulmonary, Allergy and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA, for his review of the manuscript and valuable suggestions. The authors appreciate the help of Abaseen Khan Afghan for his work on Figure 1.

Author details
Department of Medicine, University of Pittsburgh Medical Center, N713 UPMC Montefiore, 200 Lothrop Street, Pittsburgh, PA 15213, USA. *Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, 5150 Centre Avenue, Pittsburgh, PA 15232, USA. †Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Arthritis Institute, 5705 BST, 3500 Terrace Street, Pittsburgh, PA 15261, USA.

Published: 31 August 2012

References
1. Sillanpää MA, Grabovski HG. Economics of new oncology drug development. J Clin Oncol 2007, 25:209-216.
2. Aggarwal S. Targeted cancer therapies. Nat Rev Drug Discov 2010, 9:427-428.
3. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L. Rituximab in autoimmune disease—The immune complex defect hypothesis. Nat Clin Pract Rheumatol 2007, 3:866-875.
4. Maloney DG, Smith B, Rose A: Rituximab: mechanism of action and resistance. Semin Oncol 2002, 29 (1 Suppl 2) 9.
5. Taylor RP, Lindorfer MA: Drug insight: the mechanism of action of rituximab in autoimmune disease—The immune complex defect hypothesis. Nat Clin Pract Rheumatol 2007, 3:866-875.
6. Lymphoproliferative disorder; RA, rheumatoid arthritis; R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone; R-FCM, rituximab with fludarabine, cyclophosphamide, and mitoxantrone; SAE, serious adverse event; SOCD, system organ class; TTP, thrombotic thrombocytopenic purpura.
5. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.

6. Ghemmi M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Kasi P, et al. Rituximab and escalated chemotherapy in elderly patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000, 11 Suppl 1:123-126.

7. Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauser H, Martin S, Heidemann M, Aldaoud A, Panwarresch R, Ford, J, Unterhalt M, Hiddemann W. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLOGS). J Clin Oncol 2005, 23:1984-1992.

8. Ghemmi M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Walter J, Yen MF, Betticher DC, Marsinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacevic T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004, 103:4416-4423.

9. Millward PM, Bandarenoen K, Chang PP, Stagg KF, Aferyn-Annon Ann, Hay SN, Brecher ME. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion 2005; 45:1481-1486.

10. Biern SE, Kirk D, Rivera MF, Martinez AE, Khandani AH, Orlowski RZ. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. J Clin Oncol 2004, 22:423-427.

11. Tonelli AR, Lottenberg R, Allan RW, Sriram PS: Re-treatment at progression in patients with indolent non-Hodgkin's lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005, 23:1088-1095.

12. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropp M, Reis HE, Freund M, Wörmann B, Fuchs R, Planek M, Schimke J, Eimermacher H, Trümpfer L, Aldaoud A, Pawaresch R, Unterhalt M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3722-3732.

13. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417-1423.

14. Ribrag V, Gisselbrecht C, Hainoun C, Salles G, Goffet JB, Erault M, Ferme C, Briere J, Brice P, Mounier N. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer 2009, 113:4540-4546.

15. Salles G, Mounier N, de Guibert M, Morschhauser F, Doyen C, Rossi FJ, Haoun C, Brice P, Mahé B, Bouabdallah R, Audhuy B, Ferme C, Dartigues C, Feugier P, Sebban C, Merletti-Littler NR, Leclerc M, Foulou S, Lassouani M, Lassouani A. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-FLGAMS trial. Blood 2008, 112:4824-4831.

16. Hawker K, O'Conner P, Freedman MS, Calabresi PA, Antell J, Simon J, Hauser S, Yuan B, Votta M, Panter C, Zhang J, Chin P, Smith CR. OLYMPUS trial group: Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009, 66:460-471.

doi:10.1186/cc13004

Cite this article as: Kasi PM, et al.: Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. Critical Care 2012, 16:231.